JAK1 and Alzheimer disease: Tofacitinib, a JAK1/JAK3 inhibitor, has been approved for RA and psoriatic arthritis, whereas baricitinib is a JAK1/JAK2 inhibitor approved for RA and the treatment of AD in Europe.